# Antimuscarinics

|Property|Ipratropium|Tiotropium|
|--|--|
|**Class**|Muscarinic antagonist|Muscarinic antagonist|
|**Uses**|Bronchodilatation|Bronchodilatation|
|**Presentation**|MDI or solution for nebulisation|MDI|
|**Route of Administration**|Inhaled|Inhaled|
|**Dosing**|18mcg MDI, 500Âµg nebuliser||
|**Absorption**|5% bioavailability via inhaled route||
|**Metabolism**|Hepatic to inactive metabolites||
|**Elimination**|Equal renal and faecal elimination|||

Antimuscarinic agents competitively antagonise ACh at M<sub>3</sub> receptors in bronchial smooth muscle, preventing parasympathetic mediated bronchoconstriction.

|Pharmacodynamics|Antimuscarinics|
|--|--|
|**Resp**|Bronchodilation|
|**GIT**|Decreased secretions in large doses|
|**CNS**|Mydriasis if deposited in eye|

---
##References
Peck and Hill
Smith Scarth Sasada
